Biotech
4 Early-Stage Startups Tackling Bottlenecks in Cell and Gene Therapy
DealBio tracks early-stage cell and gene therapy startups across Europe and North America. These 4 are working on different execution bottlenecks that can determine whether an advanced therapy becomes practical to develop and deliver.
- Cell Therapy
- Gene Therapy
- Regenerative Medicine
- Drug Delivery
Advanced therapies depend on more than a compelling biological mechanism. Durable gene expression, reproducible tissue manufacturing, controlled delivery of living cells and workable patient-specific treatment processes can all become rate-limiting steps.
Across this group, the common opportunity is making advanced therapies more repeatable: sustaining gene expression, manufacturing tissue consistently, placing living cells precisely and simplifying patient-specific treatment. Each startup is addressing a point where execution can determine whether a promising therapy becomes practical to scale.
At a Glance
- Houdini BioUnited Kingdom2025Durable expression from therapeutic DNA
- Ibnova TherapeuticsDenmark2026Scalable engineered heart tissue
- VRiTCanada2025Direct delivery of cells to wounds
- Circle BioNetherlands2024Personalized CAR-T treatment workflow
Using machine learning to redesign therapeutic DNA and reduce gene silencing.
- Country
United Kingdom- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
- Founders
Why Houdini Bio stands out
Houdini Bio is addressing a practical limitation in genetic medicines: therapeutic DNA can be switched off by cells over time. The startup raised a £1.5 million pre-seed round led by Science Creates to develop a machine-learning platform for redesigning DNA around that problem.
The underlying approach is tied directly to the founders' research background. Rather than treating expression loss as a downstream manufacturing issue, Houdini Bio is designing around it at sequence level before a construct reaches the laboratory.
What Houdini Bio is building
ARCANA uses machine learning to redesign therapeutic DNA while preserving the protein it encodes. The aim is to reduce gene silencing, the cellular process that can turn down or shut off expression from introduced DNA, so a therapeutic construct keeps producing its intended protein for longer.
The software is intended to help gene-therapy and cell-engineering teams rank redesigned sequences before committing to slower experimental work. That makes Houdini Bio an enabling layer for programs where durable expression is part of the product requirement.
Developing stem-cell-derived heart tissue patches for severe heart failure.
- Country
Denmark- Founded
- 2026
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why Ibnova Therapeutics stands out
Ibnova Therapeutics is taking engineered heart tissue toward a clinical product rather than leaving it as a laboratory model. The startup joined BioInnovation Institute Venture Lab with up to €500,000 in financing and is working with the Novo Nordisk Foundation Cellerator on process development and scale-up.
Its founding research has restored heart function in animal models, while co-founder James Hudson contributed to earlier cardiac-patch work that reached a Phase 1/2 trial. That gives the team direct experience with the manufacturing and translation questions that determine whether engineered tissue can move beyond proof of concept.
What Ibnova Therapeutics is building
Ibnova Therapeutics grows vascularized human heart-muscle patches from stem cells. The patch combines heart-muscle cells with vascular cells and is designed to be attached over damaged myocardium after a heart attack.
The product is intended to be allogeneic, meaning donor-derived cells are manufactured for use in multiple patients, and available off the shelf. The development challenge therefore combines cell biology with reproducible manufacturing, storage and implantation.
03
VRiT
Developing a handheld bioprinter that deposits stem-cell therapy onto skin wounds.
- Country
Canada- Founded
- 2025
- Sector
- Medtech
- Funding stage
- Seed or earlier
- Founders
Why VRiT stands out
VRiT brings tissue engineering to the treatment site. Co-founder Axel Guenther is senior author of the 2018 peer-reviewed study describing a handheld device that formed tissue directly on a wound and is named on two granted US patents covering the approach.
A large-animal burn study reported faster skin regrowth and new blood-vessel formation after stem-cell-containing material was printed onto wounds. That evidence supports the core idea behind VRiT: make cell placement part of a practical surgical workflow rather than a separate tissue-manufacturing step.
What VRiT is building
INSITE is a handheld bioprinter, a device that deposits biomaterial or cells directly onto tissue, designed for burns, trauma wounds and surgical defects. Its handheld format lets clinicians follow irregular wound shapes rather than moving the patient to a fixed printing system.
VRiT's SHIELD program adds mesenchymal stem cells, cells that can support tissue repair, to the printed material. The product thesis is controlled cell delivery at the point of care, with the device and biological material developed as one workflow.
Developing tailored CAR-T therapies for rheumatoid arthritis and multiple sclerosis.
- Country
Netherlands- Founded
- 2024
- Sector
- Biotech
- Funding stage
- Seed or earlier
- Founders
Why Circle Bio stands out
Circle Bio is being built by founders with direct experience taking personalized cell therapies through company building and clinical development. Maarten Zandvliet and Tol Trimborn previously worked at CellPoint, which Galapagos acquired for €125 million upfront plus up to €100 million in milestones.
That experience is relevant to the current product because CAR-T, a therapy made by engineering a patient's own T cells to recognize a target, depends on more than target biology. Collection, manufacturing, conditioning and return of the cells all have to work as a repeatable treatment pathway.
What Circle Bio is building
Circle Bio is developing tailored CAR-T therapies for autoimmune disease, beginning with rheumatoid arthritis and multiple sclerosis. The approach uses a patient's own immune cells and is designed around a simplified treatment workflow.
The startup's development challenge is therefore operational as well as biological: turn a personalized cell product into a process that can be manufactured consistently and fit specialist care without recreating every step from scratch for each program.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
The four startups sit at different points in advanced therapy development, but each is trying to make a fragile step more predictable. Houdini Bio works upstream at DNA design, Ibnova Therapeutics at engineered-tissue manufacturing, VRiT at point-of-care cell placement and Circle Bio at the operational pathway around a personalized cell therapy.
For investors, that widens the lens beyond the therapeutic target. Platforms that remove a repeatable bottleneck can create value across multiple programs, particularly when the improvement is measurable in expression, manufacturing consistency, delivery precision or treatment logistics.
Methodology
DealBio selected these startups from its coverage of early-stage health and longevity startups, focusing on businesses that address a distinct bottleneck in cell or gene therapy development and delivery. The selection spans therapeutic DNA design, engineered tissue, cell delivery and personalized CAR-T workflows.
DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.